<DOC>
	<DOCNO>NCT02535533</DOCNO>
	<brief_summary>This Phase 1 trial safety preliminary efficacy combination axitinib selenomethionine ( SLM ) adult patient advance metastatic clear cell renal cell carcinoma ( CCRCC ) . This two part study consist dose escalation expansion study .</brief_summary>
	<brief_title>SLM + Axitinib Clear Cell RCC</brief_title>
	<detailed_description>This Phase 1 trial safety preliminary efficacy combination axitinib selenomethionine ( SLM ) adult patient advance metastatic clear cell renal cell carcinoma ( CCRCC ) . This two part study consist dose escalation expansion study . Dose-Escalation Part 1 ( 6-12 patient ) : SLM give twice daily 14 day follow SLM daily combination axitinib 5 mg twice daily titration accord package insert patient advance renal cell carcinoma . Treatment continue disease progression unacceptable toxicity . Expansion Part 2 : In phase ( approximately 19 patient ) , treat maximum tolerate dose ( MTD ) SLM determine Escalation Part 1 . It give orally twice daily 14 day , follow SLM daily combination axitinib 5 mg twice daily titration accord package insert patient advance renal cell carcinoma . Treatment continue disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>Histologically radiologically confirm advanced metastatic CCRCC patient least one prior systemic therapy , include axitinib . Written voluntary inform consent . At least one Response Evaluation Criteria In Solid Tumors ( RECIST ) define target lesion . *Patient must document disease progression . Renal function ( creatinine level within normal institutional limit , creatinine clearance &gt; 15 mL/min/1.73 m2 patient creatinine level institutional normal , calculate use CockcroftGault formula ) . Liver function ( AST/ALT &lt; 2.5 X institutional upper limit normal OR &lt; 5 X institutional upper limit normal case liver metastasis ; Total bilirubin ≤ 1.5 time ULN . ) Adequate hematological lab value include : Absolute Neutrophil Count ( ANC ) ≥ 1.0 x 109/L , Platelets ≥ 100 x 109/L , Hemoglobin ≥ 9.0 g/dL Eastern Cooperative Oncology Group ( ECOG ) performance status 0 ( fully active , able carry predisease performance without restriction ) 1 ( restrict physically strenuous activity ambulatory able carry work light sedentary nature , light housework office work ) 2 ( Ambulatory capable selfcare unable carry work activity ; 50 % waking hour ) . Age least 18 year . Life expectancy 12 week . 2 week since end previous systemic radiation treatment ( 4 week bevacizumab plus interferonalfa ) . Any cancer patient diseasefree less 5 year ( except treat cure basalcell squamouscell skin cancer , superficial bladder cancer , treat carcinoma situ cervix , breast , bladder treat localized prostate cancer undetectable PSA 2 year ) . Symptomatic untreated metastasis central nervous system . Subject pregnant lactating Preexisting uncontrolled hypertension define &gt; 150/90 mm Hg medication . Present use anticipate need cytochrome P450 ( CYP ) 3A4inhibiting , CYP3A4inducing drug ( e.g. , ketoconazole , itraconazole , clarithromycin , atazanavir , indinavir , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , voriconazole , rifampin , phenytoin , carbamazepine , rifabutin , rifapentin , phenobarbital , St. John 's wort , bosentan , efavirenz , etravirine , modafinil , nafcillin ) .Myocardial infarction , uncontrolled angina , congestive heart failure , cerebrovascular accident within previous 6 month . Subjects history deep vein thrombosis pulmonary embolism , provider discretion . Myocardial infarction , uncontrolled angina , congestive heart failure , cerebrovascular accident within previous 12 month ; deep vein thrombosis pulmonary embolism within previous 6 month . Major surgery within 4 week start study treatment . Known HIV acquire immunodeficiency syndromerelated disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Kidney cancer</keyword>
	<keyword>Selenium ( Se )</keyword>
</DOC>